Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACCE Model System for Collecting, Analyzing and Disseminating Information on Genetic Tests

This website is archived for historical purposes and is no longer being maintained or updated.

FBR logoIn September 2000, the Office of Public Health Genomics, CDC, funded a new cooperative agreement with the Foundation for Blood Research (FBR). FBR is a nonprofit research organization with expertise in clinical and laboratory investigation. They have carried out a wide array of studies evaluating test performance, quality control, and effectiveness. The aim of this project was to develop a model system for assembling, analyzing, disseminating and updating existing data on the safety and effectiveness of DNA-based genetic tests and testing algorithms. (More detail about the process and definitions of terms can be found at ACCE Project ).

Five tests for different disorders have been evaluated for the components of analytical validity, clinical validity, clinical utility, and related ethical/legal/social issues. This evaluation was consistent with preliminary recommendations of the Department of Health and Human Services Secretary's Advisory Committee on Genetic Testing.

Draft Genetic Test Reviews
Final drafts of component sections of Genetic Test Reviews are posted online for viewing. Full titles of the five reviews are listed below and references for peer reviewed journal articles derived from these drafts are provided. The matrix below indicates components that are currently available in Acrobat PDF and/or HTML formats. Click on the corresponding check mark icon to view. For those sections available in PDF format, you will need Free Adobe Acrobat Software .

*click the check icon to view the PDF

  Cystic Fibrosis1 Hemochromatosis2 Venous Thromboembolism3 Breast & Ovarian Cancer4 Colorectal Cancer5
Introduction
(Genetic Test Brief)
N/A
N/A
N/A
Disorder & Setting
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 55 KB]
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 89 KB]
[PDF 348 KB]
[PDF 249 KB]
Analytic Validity
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 559 KB]
 
[PDF 987 KB]
[PDF 350 KB]
Clinical Validity
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 436 KB]
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 497 KB]
 
[PDF 1.5 MB]
[PDF 526 KB]
Clinical Utility
N/A
[PDF 284 KB]
[PDF 5.2 MB]
Ethical, Legal & Social Issues
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 42 KB]
N/A
N/A
N/A
Master Reference List and Glossary
check - link to Cystic Fibrosis Ethical, Legal and Social Issues report[PDF 248 KB]
N/A
N/A
N/A

(1) Prenatal Screening for Cystic Fibrosis via CFTR Carrier Testing
(2) Screening for Hereditary Hemochromatosis in Adults via HFE Mutation Testing
(3) Testing for Factor V Leiden and Prothrombin Mutations as a Risk Factor for Recurrent Venous Thrombosis in Adults
(4) Family History and BRCA 1/2 Testing for Identifying Women at Risk for Inherited Breast/Ovarian Cancer
(5) DNA Testing Strategies Aimed at Preventing HNPCC


References
  1. Palomaki GE, Haddow JE, Bradley LA, Fitzsimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med 2002; 4:90-4.
  2. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, McGinnis MJ, Prior TW, Popovich BW, Watson MS. Standards and Guidelines for CFTR Testing. Genet Med 2002; 4:379-91.
  3. Haddow JE, Palomaki GE. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In: Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Khoury M, Little J, Burke W (eds.), Oxford University Press, pp. 217-233, 2003.
  4. Palomaki GE, Bradley LA, Richards CS, Haddow JE. Analytic validity of cystic fibrosis testing: A preliminary estimate. Genet Med 2003; 5:15-20.
  5. Palomaki GE, Bradley LA, Richards CS, Haddow JE. Analytic validity of cystic fibrosis testing: A preliminary estimate. Genet Med 2003; 5:15-20.
  6. Palomaki GE, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW. Estimated analytic validity of HFE C282Y mutation testing in population screening: The potential value of confirmatory testing. Genet Med 2003;5:440-3.
  7. Haddow JE, Palomaki GE, McClain M, Craig W: Hereditary hemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 2003;10:11-13.
  8. Palomaki GE, FitzSimmons SC , Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 2004;6:405-414.
  9. Watson MS, Cutting GR, Desnik RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387-391.
  10. McClain MR, Palomaki GE, Nathanson KL, Haddow JE: Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28-33.
  11. McClain MR, Nathanson KL, Palomaki GE, Haddow JE: An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005;7:34-9.
Top